Pyxis Oncology, Inc. (PYXS)

USD 1.52

(-6.75%)

Market Cap (In USD)

90.38 Million

Revenue (In USD)

-

Net Income (In USD)

-73.79 Million

Avg. Volume

598.73 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.5-6.85
PE
-
EPS
-
Beta Value
1.276
ISIN
US7473241013
CUSIP
747324101
CIK
1782223
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Lara S. Sullivan M.D., MBA
Employee Count
-
Website
https://www.pyxisoncology.com
Ipo Date
2021-10-08
Details
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.